Pharmacological properties of oral antibiotics for the treatment of uncomplicated urinary tract infections

References

• Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonehritis in women: a 2010 update by the IDSA and European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103–20.10.1093/cid/ciq257
   PubMed Web of Science ®Google Scholar
• Bonkat G, Pickard R, Bartoletti R, Bruyère F, Geerlings SE, Wagenlehner F, et al. Guidelines on urological infections. European Association of Urology; 2017.
   Google Scholar
• Battaglia M, Cai T, Concia E, De Nunzio C, Mazzei T, Pea F, et al. Raccomandazioni in tema di diagnosi, trattamento e profilassi delle infezioni delle vie urinarie, versione 1 anno 2015 SIU-UTI. Available from: https://www.siu.it/files/uploads/Linee_Guida_SIU_UTI_2015.pdf
   Google Scholar
• Neu HC. Optimal characteristics of agents to treat uncomplicated urinary tract infections. Infection. 1992;20(S4):S266–71.10.1007/BF01710012
   PubMedGoogle Scholar
• Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1–10.10.1086/cid.1998.26.issue-1
   PubMed Web of Science ®Google Scholar
• Rodvold KA. Pharmacodynamics of antiinfective therapy: taking what we know to the patient’s bedside. Pharmacotherapy. 2001;21(11s):319s–30s.10.1592/phco.21.18.319S.33904
   PubMedGoogle Scholar
• McKinnon PS, Davis SL. Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious disease. Eur J Clin Microbiol Infect Dis. 2004;23(4):271–88.10.1007/s10096-004-1107-7
   PubMed Web of Science ®Google Scholar
• Andes D, Craig WA. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents. 2002;19(4):261–8.10.1016/S0924-8579(02)00022-5
   PubMed Web of Science ®Google Scholar
• Nicolau DP. Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling. J Infect Chemother. 2003;9(4):292–6.10.1007/s10156-003-0279-X
   PubMedGoogle Scholar
• Appelbaum PC, Hunter PA. The fluoroquinolone antibacterials: past, present and future perspectives. Int J Antimicrob Agents. 2000;16(1):5–15.10.1016/S0924-8579(00)00192-8
   PubMed Web of Science ®Google Scholar
• Peterson LR. Quinolone molecular structure‐activity relationships: what we have learned about improving antimicrobial activity. Clin Infect Dis. 2001;33(Suppl 3):S180–6.10.1086/cid.2001.33.issue-s3
   PubMedGoogle Scholar
• von Rosenstiel N, Adam D. Quinolone antibacterials: an update of their pharmacology and therapeutic use. Drugs. 1994;47(6):872–901.10.2165/00003495-199447060-00003
   PubMed Web of Science ®Google Scholar
• Novelli A, Cassetta MI, Fallani S, Periti P. Clinical pharmacokinetics and tissue penetration of ciprofloxacin after a single or multiple oral dose of 250 or 500 mg. Eur J Clin Microbiol Infect Dis. 1991;20:367–9.
   Google Scholar
• Schaeffer AJ. The expanding role of fluoroquinolones. Am J Med. 2002;113(1A):S45–54.10.1016/S0002-9343(02)01059-8
   Google Scholar
• Mazzei T, Novelli A, Reali EF, Balocchini E, Boni S, De Stasio A, et al. Farmacocinetica e penetrazione tissutale della oflossacina. Farmaci & Terapia. 1987;4(4):244–9.
   Google Scholar
• Novelli A. Antimicrobial prophylaxis in surgery: the role of pharmacokinetics. J Chemother. 1999 Dec;11(6):565–72.10.1179/joc.1999.11.6.565
   PubMed Web of Science ®Google Scholar
• Pickerill KE, Paladino JA, Schentag JJ. Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters. Pharmacotherapy. 2000;20(4):417–28.10.1592/phco.20.5.417.35062
   PubMed Web of Science ®Google Scholar
• Gupta K, Hooton TM, Stamm WE. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann Intern Med. 2001;135(1):41–50.10.7326/0003-4819-135-1-200107030-00012
   PubMed Web of Science ®Google Scholar
• Picollo R, Brion N, Gualano V, Millérioux L, Marchetti M, Rosignoli MT, et al. Pharmacokinetics and tolerability of prulifloxacin after single oral administration. Arzneimittel-Forschung. 2003;53(3):201–5.
   PubMed Web of Science ®Google Scholar
• Bolon MK. The newer fluoroquinolones. Infect Dis Clin North Am. 2009;23(4):1027–51.10.1016/j.idc.2009.06.003
   PubMed Web of Science ®Google Scholar
• Frimodt-Møller N. Correlation between pharmacokinetic/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection. Int J Antimicrob Agents. 2002;19(6):546–53.10.1016/S0924-8579(02)00105-X
   PubMed Web of Science ®Google Scholar
• Erdogan-Yildirim Z, Burian A, Manafi M, Zeitlinger M. Impact of pH on bacterial growth and activity of recent fluoroquinolones in pooled urine. Res Microbiol. 2011;162(3):249–52.10.1016/j.resmic.2011.01.004
   PubMed Web of Science ®Google Scholar
• L Yang, K Wang, H Li, JD Denstedt, PA Cadieux. The influence of urinary pH on antibiotic efficacy against bacterial uropathogens. Urology. 2014;84(3): 731 e1-7.
   Web of Science ®Google Scholar
• Zhanel GG, Karlowsky JA, Davidson RJ, Hoban DJ. Influence of human urine on the in vitro activity and postantibiotic effect of ciprofloxacin against Escherichia coli. Chemotherapy. 1991;37(3):218–23.10.1159/000238857
   PubMed Web of Science ®Google Scholar
• Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA. 1998;279(2):125–9.10.1001/jama.279.2.125
   PubMed Web of Science ®Google Scholar
• Schentag JJ. Clinical pharmacology of the fluoroquinolones: studies in human dynamic/kinetic models. Clin Infect Dis. 2000;31(Suppl 2):S40–4.10.1086/314059
   PubMedGoogle Scholar
• Ball P. Future of the quinolones. Semin Respir Infect. 2001;16(3):215–24.10.1053/srin.2001.25628
   PubMedGoogle Scholar
• Kim GK. The risk of fluoroquinolone-induced tendinopathy and tendon rupture: what does the clinician need to know? J Clin Aesthet Dermatol. 2010;3(4):49–54.
   PubMedGoogle Scholar
• Shepherd AK, Pottinger PS. Management of urinary tract infections in the era of increasing antimicrobial resistance. Med Clin North Am. 2013;97(4):737–57.10.1016/j.mcna.2013.03.006
   PubMed Web of Science ®Google Scholar
• Cockerill FR, Edson RS. Trimethoprim-sulfamethoxazole. Mayo Clin Proc. 1991;66(12):1260–9.10.1016/S0025-6196(12)62478-1
   PubMed Web of Science ®Google Scholar
• Hutabarat RM, Unadkat JD, Sahajwalla C, McNamara S, Ramsey B, Smith AL. Disposition of drugs in cystic fibrosis. I. Sulfamethoxazole and trimethoprim. Clin Pharmacol Ther. 1991;49(4):402–9.10.1038/clpt.1991.47
   PubMed Web of Science ®Google Scholar
• Raz R, Chazan B, Kennes Y, Colodner R, Rottensterich E, Dan M, et al. Empiric use of trimethoprim‐sulfamethoxazole (TMP‐SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP‐SMX–resistant uropathogens. Clin Infect Dis. 2002;34(9):1165–9.10.1086/cid.2002.34.issue-9
   PubMed Web of Science ®Google Scholar
• Antoniou T, Gomes T, Mamdani MM, Yao Z, Hellings C, Garg AX, et al. Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study. BMJ. 2011;343:d5228.10.1136/bmj.d5228
   PubMedGoogle Scholar
• Fraser TN, Avellaneda AA, Graviss EA, Musher DM. Acute kidney injury associated with trimethoprim/sulfamethoxazole. J Antimicrob Chemother. 2012;67(5):1271–7.10.1093/jac/dks030
   PubMed Web of Science ®Google Scholar
• Nickel JC. Management of urinary tract infections: historical perspective and current strategies: part 2 – modern management. J Urol. 2005;173(1):27–32.10.1097/01.ju.0000141497.46841.7a
   PubMed Web of Science ®Google Scholar
• MacGowan A. Revisiting Beta-lactams – PK/PD improves dosing of old antibiotics. Curr Opin Pharmacol. 2011;11(5):470–6.10.1016/j.coph.2011.07.006
   PubMed Web of Science ®Google Scholar
• Klepser ME, Marangos MN, Patel KB, Nicolau DP, Quintiliani R, Nightingale CH. Clinical pharmacokinetics of newer cephalosporins. Clin Pharmacokinet. 1995;28(5):361–84.10.2165/00003088-199528050-00003
   PubMed Web of Science ®Google Scholar
• Lode H, Fassbender M, Schaberg T, Borner K, Koeppe P. Comparative pharmacokinetics of the new oral cephalosporins. Drugs. 1994;47(Suppl 3):10–20.10.2165/00003495-199400473-00004
   PubMedGoogle Scholar
• Perry CM, Brogden RN. Cefuroxime axetil: a review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1996;52(1):125–58.10.2165/00003495-199652010-00009
   PubMed Web of Science ®Google Scholar
• Periti P, Novelli A, Mini E, Mazzei T, Cassetta MI. Clinical pharmacokinetics of cefpodoxime proxetil in older patients. In: Dieter Adam, Hartmut Lode and Ethan Rubinstein. Recent Advances in Chemotherapy, Antimicrobial Section I. Proceedings of the 17th International Congress of Chemotherapy, Berlin, 1991. Monaco, Germania: Futuramed; 1992. p. 326–7.
   Google Scholar
• Heikkilä A, Pyykkö K, Erkkola R, Lisalo E. The pharmacokinetics of mecillinam and pivmecillinam in pregnant and non-pregnant women. Br J Clin Pharmacol. 1992;33(6):629–33.10.1111/bcp.1992.33.issue-6
   PubMed Web of Science ®Google Scholar
• Roholt K, Nielsen B, Kristensen E. Pharmacokinetic studies with mecillinam and pivmecillinam. Chemotherapy. 1975;21(3–4):146–66.10.1159/000221856
   PubMed Web of Science ®Google Scholar
• Bornemann LD, Castellano S, Lin AH, Enthoven D, Patel IH. Influence of food on bioavailability of amdinocillin pivoxil. Antimicrob Agents Chemother. 1988;32(4):592–4.10.1128/AAC.32.4.592
   PubMed Web of Science ®Google Scholar
• Graninger W. Pivmecillinam–therapy of choice for lower urinary tract infection. Int J Antimicrob Agents. 2003;22(Suppl 2):73–8.10.1016/S0924-8579(03)00235-8
   PubMed Web of Science ®Google Scholar
• Sullivan A, Edlund C, Svenungsson B, Emtestam L, Nord CE. Effect of perorally administered pivmecillinam on the normal oropharyngeal, intestinal and skin microflora. J Chemother. 2001;13(3):299–308.10.1179/joc.2001.13.3.299
   PubMed Web of Science ®Google Scholar
• Kerrn MB, Frimodt-Møller N, Espersen F. Urinary concentrations and urine ex-vivo effect of mecillinam and sulphamethizole. Clin Microbiol Infect. 2004;10(1):54–61.10.1111/j.1469-0691.2004.00737.x
   PubMed Web of Science ®Google Scholar
• Ricciardi W, Giubbini G, Laurenti P. Surveillance and control of antibiotic resistance in the mediterranean region. Mediterr J Hematol Infect Dis. 2016;8(1):e2016036.10.4084/mjhid.2016.036
   PubMedGoogle Scholar
• Mody L, Juthani-Mehta M. Urinary tract infections in older women: a clinical review. JAMA. 2014;311(8):844–54.10.1001/jama.2014.303
   PubMed Web of Science ®Google Scholar
• Mazzulli T, Skulnick M, Small G, Marshall W, Hoban DJ, Zhanel GG, et al. Susceptibility of community gram-negative urinary tract isolates to mecillinam and other oral agents. Can J Infect Dis. 2001;12(5):289–92.10.1155/2001/601743
   PubMedGoogle Scholar
• Hof H. Antimicrobial therapy with nitroheterocyclic compounds, for example, metronidazole and nitrofurantoin. Immun Infekt. 1988;16(6):220–5.
   PubMedGoogle Scholar
• Ben-Noun L. Drug-induced respiratory disorders: incidence, prevention and management. Drug Saf. 2000;23(2):143–64.10.2165/00002018-200023020-00005
   PubMed Web of Science ®Google Scholar
• Adkison KK, Vaidya SS, Lee DY, Koo SH, Li L, Mehta AA, et al. The ABCG2 C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects. Br J Clin Pharmacol. 2008;66(2):233–9.10.1111/bcp.2008.66.issue-2
   PubMed Web of Science ®Google Scholar
• Komp Lindgren P, Klockars O, Malmberg C, Cars O. Pharmacodynamic studies of nitrofurantoin against common uropathogens. J Antimicrob Chemother. 2015;70(4):1076–82.
   PubMed Web of Science ®Google Scholar
• Mattappalil A, Mergenhagen KA. Neurotoxicity with antimicrobials in the elderly: a Review. Clin Ther. 2014;36(11):1489–511.10.1016/j.clinthera.2014.09.020
   PubMed Web of Science ®Google Scholar
• Appleyard S, Saraswati R, Gorard DA. Autoimmune hepatitis triggered by nitrofurantoin: a case series. J Med Case Rep. 2010;4:311.10.1186/1752-1947-4-311
   PubMedGoogle Scholar
• Smyk DS, Bogdanos DP, Kriese S, Billinis C, Burroughs AK, Rigopoulou EI, et al. Urinary tract infection as a risk factor for autoimmune liver disease: from bench to bedside. Clin Res Hepatol Gastroenterol. 2012;36(2):110–21.10.1016/j.clinre.2011.07.013
   PubMed Web of Science ®Google Scholar
• Mezzatesta ML, La Rosa G, Maugeri G, Zingali T, Caio C, Novelli A, et al. In vitro activity of fosfomycin trometamol and other oral antibiotics against multidrug-resistant uropathogens. Int J Antimicrob Agents. 2017;49(6):763–6.10.1016/j.ijantimicag.2017.01.020
   PubMed Web of Science ®Google Scholar
• Patel SS, Balfour JA, Bryson HM. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs. 1997;53(4):637–56.10.2165/00003495-199753040-00007
   PubMed Web of Science ®Google Scholar
• Gobernado M. Fosfomycin. Rev Esp Quimioter. 2003;16(1):15–40.
   PubMedGoogle Scholar
• Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis. 2011;15(11):e732–9.10.1016/j.ijid.2011.07.007
   PubMed Web of Science ®Google Scholar
• Fuchs PC, Barry AL, Brown SD. Fosfomycin tromethamine susceptibility of outpatient urine isolates of Escherichia coli and Enterococcus faecalis from ten North American medical centres by three methods. J Antimicrob Chemother. 1999;43(1):137–40.10.1093/jac/43.1.137
   PubMed Web of Science ®Google Scholar
• Garcia-Rodriguez JA, Trujillano Martin I, Baquero F, Cisterna R, Gobernado M, Linares F, et al. vitro activity of fosfomycin trometamol against pathogens from urinary tract infections: a Spanish multicenter study. J Chemother. 1997;9(6):394–402.10.1179/joc.1997.9.6.394
   PubMed Web of Science ®Google Scholar
• Liao RZ, Thiel W. Determinants of regioselectivity and chemoselectivity in fosfomycin resistance protein FosA from QM/MM calculations. J Phys Chem B. 2013;117(5):1326–36.10.1021/jp4002719
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Walkty AJ, Karlowsky JA. Fosfomycin: a first-line oral therapy for acute uncomplicated cystitis. Can J Infect Dis Med Microbiol. 2016 May 10 [ epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Mazzei T, Cassetta MI, Fallani S, Arrigucci S, Novelli A. Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections. Int J Antimicrob Agents. 2006;28(Suppl 1):S35–41.10.1016/j.ijantimicag.2006.05.019
   PubMedGoogle Scholar
• Mei Q, Ye Y, Zhu YL, Cheng J, Chang X, Liu YY, et al. Testing the mutant selection window hypothesis in vitro and in vivo with Staphylococcus aureus exposed to fosfomycin. Eur J Clin Microbiol Infect Dis. 2015;34(4):737–44.10.1007/s10096-014-2285-6
   PubMed Web of Science ®Google Scholar
• Roussos N, Karageorgopoulos DE, Samonis G, Falagas ME. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int J Antimicrob Agents. 2009;34(6):506–15.10.1016/j.ijantimicag.2009.08.013
   PubMed Web of Science ®Google Scholar
• Borghi CM, La Veneziana D, Riva A, Marca G, Zanninin G. Concentrazioni nel siero e nel tessuto prostatico di fosfomicina con fosfomicina-trometamolo, nuovo derivato della fosfomicina con elevata biodisponibilità per somministrazione orale. Farmaci & Terapia. 1986;3(3):216–20.
   Google Scholar
• Gardiner BJ, Mahony AA, Ellis AG, Lawrentschuk N, Bolton DM, Zeglinski PT, et al. Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis? Clin Infect Dis. 2014;58(4):e101–5.10.1093/cid/cit704
   PubMed Web of Science ®Google Scholar
• Periti P, Novelli A, Reali EF, Del Bono GP, Fontana P. Prophylactic chemotherapy with fosfomycin trometamol salt in transurethral prostatectomy. In: Neu HC, Williams JD. New trends in urinary tract infections. Basel: Karger; 1988. p. 207–23.
   Google Scholar
• Krcmery S, Hromec J, Demesova D. Treatment of lower urinary tract infection in pregnancy. Int J Antimicrob Agents. 2001;17(4):279–82.10.1016/S0924-8579(00)00351-4
   PubMed Web of Science ®Google Scholar